CTNNA1/CTNNA2 Antibody

What are CTNNA1 and CTNNA2 proteins and what are their basic functions?

CTNNA1 encodes alpha-E-catenin (α-E-catenin), which is expressed ubiquitously in normal tissues, while CTNNA2 encodes alpha-N-catenin (α-N-catenin), which is specifically expressed in neural tissues, with strongest expression in fetal and adult brain, including the developing cortical plate and marginal zone of 20-week-old human fetal brain . These proteins are members of the catenin family and function as key components of cell-cell adhesion complexes.

The alpha-catenin proteins connect the cadherin-beta-catenin complex to the actin cytoskeleton, playing crucial roles in:

• Maintaining cellular structure integrity

• Regulating cell-cell adhesion

• Cell signaling

• Tumor suppression in various cancers

Both proteins have been implicated in cancer progression, with growing evidence suggesting their tumor suppressor functions, particularly in neural crest-derived tumors like neuroblastoma .

What applications are CTNNA1/CTNNA2 antibodies commonly used for in research?

CTNNA1/CTNNA2 antibodies are versatile reagents with multiple applications in molecular and cellular research:

The optimal dilutions should be determined by each researcher based on their specific experimental conditions and antibody lot. When citing the use of these antibodies, the proper format is: Affinity Biosciences Cat# AF9036, RRID:AB_2843227 .

How do CTNNA1 and CTNNA2 expression patterns differ across normal tissues and cancer cells?

The expression patterns of these proteins show distinctive tissue distribution and alterations in cancer:

CTNNA1 (α-E-catenin):

• Expressed ubiquitously across normal tissues

• Expression is frequently decreased or lost in various cancers

• Serves as a prognostic marker in multiple cancer types

CTNNA2 (α-N-catenin):

• Neural-specific expression pattern

• Strongest expression in fetal and adult brain

• Specifically expressed in the developing cortical plate and marginal zone of human fetal brain

• Expression varies across neuroblastoma cell lines (from negative to abundant)

• Shows clinical stage-dependent expression in neuroblastoma, with significantly decreased expression in stage 4 compared to other stages

In neuroblastoma cell lines, immunoblotting has revealed varied expression patterns:

• Negative expression: SK-N-AS and SK-N-SH cell lines

• Moderate expression: BE(2)-M17, IMR-32, and LAN-1

• Abundant expression: BE(2)-C, SK-N-DZ, and SH-SY5Y

No correlative expression has been observed between MYCN and CTNNA2 in neuroblastoma cell lines .

How should I design experiments to investigate CTNNA1/CTNNA2 function in cancer models?

When designing experiments to study CTNNA1/CTNNA2 in cancer models, consider this multi-faceted approach:

In vitro studies:

• Cell line selection: Choose appropriate cancer cell lines with varying endogenous levels of CTNNA1/CTNNA2. For neuroblastoma studies, consider:

  • Negative expression: SK-N-AS, SK-N-SH

  • Moderate expression: BE(2)-M17, IMR-32, LAN-1

  • High expression: BE(2)-C, SK-N-DZ, SH-SY5Y

• Gene modulation approaches:

  • Overexpression: Establish stable cell lines expressing CTNNA1 or CTNNA2

  • Knockdown/Knockout: Use siRNA, shRNA, or CRISPR-Cas9 technology

• Functional assays:

  • Clonogenic assay to assess cell proliferation

  • Anchorage-independent growth (soft agar colony formation)

  • Migration and invasion assays

  • Cell-cell adhesion measurements

In vivo studies:

• Xenograft models: Subcutaneously inject cells with modulated CTNNA1/CTNNA2 expression into immunocompromised mice

• Measurement parameters:

  • Tumor formation rate

  • Tumor volume and mass

  • Confirmation of CTNNA1/CTNNA2 expression in tumor tissues via immunohistochemistry

  • Analysis of angiogenesis using CD31/PECAM-1 staining

  • Cell proliferation assessment using mitosis markers like phospho-Histone H3 (Ser10)

For example, in studies involving neuroblastoma, researchers established stable CTNNA2-overexpressing cell lines and observed significant reduction in cell proliferation (77% in BE(2)-C and 52% in SK-N-AS) through clonogenesis assays .

What are the key considerations when using CTNNA1/CTNNA2 antibodies for protein detection in cancer tissues?

When using CTNNA1/CTNNA2 antibodies for cancer tissue analysis, consider these critical factors:

Antibody selection and validation:

• Verify antibody specificity through appropriate controls (positive and negative)

• Use antibodies recognizing epitopes from different regions of the protein

• Consider both monoclonal and polyclonal antibodies for complementary approaches

Sample preparation optimization:

• Fixation methods significantly impact epitope availability

• For paraffin sections, optimize antigen retrieval methods

• For frozen sections, determine optimal fixation time

Signal detection considerations:

• The molecular weight of CTNNA1/CTNNA2 is approximately 100kDa, with calculated weights of 100-105kD

• When analyzing co-expression with other markers (e.g., neuronal marker NSE), sequential staining or dual immunofluorescence may be required

• For quantitative analysis, establish standardized scoring methods

Technical validation approaches:

• When possible, confirm immunohistochemistry results with other methods like Western blotting

• Include appropriate tissue controls in each experiment

• Consider the subcellular localization pattern (membranous, cytoplasmic, nuclear) for proper interpretation

In neuroblastoma xenograft models, researchers have successfully used immunohistochemical staining to confirm CTNNA2 and NSE expression in tumor tissues, providing validation of their experimental approach .

How can I effectively analyze CTNNA1/CTNNA2 expression data in relation to patient outcomes?

To effectively analyze CTNNA1/CTNNA2 expression data in relation to patient outcomes, implement this comprehensive approach:

Data collection and normalization:

• Ensure gene expression data is properly normalized

• Consider batch effects and platform differences when using multi-cohort data

• Include relevant clinical parameters (stage, grade, treatment history)

Survival analysis methodologies:

• Use Kaplan-Meier curves to visualize survival differences

• Apply log-rank tests to assess statistical significance

• Perform multivariate Cox regression to adjust for confounding variables

Patient stratification strategies:

• Define high/low expression groups using:

  • Median split

  • Quartile analysis

  • Optimized cutpoints (e.g., maximally selected rank statistics)

• Consider dividing patients based on molecular subtypes:

  • For neuroblastoma: MYCN-amplified vs. non-MYCN-amplified subgroups

  • For lung adenocarcinoma: CTNNA2 wild-type vs. CTNNA2 mutant-type

Data visualization and interpretation:

• Create forest plots for hazard ratios across different subgroups

• Use waterfall plots to show expression distribution

• Incorporate clinicopathological correlations

What are the mechanisms by which CTNNA2 mutations alter the immune microenvironment in cancer?

CTNNA2 mutations profoundly reshape the tumor immune microenvironment through multiple interconnected mechanisms:

Increased neoantigen load and tumor mutation burden:

• CTNNA2-mutant lung adenocarcinoma (LUAD) patients exhibit significantly higher tumor mutation burden (TMB) compared to wild-type patients

• These patients also display increased tumor neoantigens, which can enhance tumor immunogenicity and recognition by the immune system

Altered cytokine and chemokine expression:

• CTNNA2 mutations correlate with elevated expression of critical chemokines including CXCL9, which recruits T cells to the tumor microenvironment

• Enhanced expression of cytolytic markers like granzyme B (GZMB), indicating increased cytotoxic immune activity

Regulatory immune receptor modulation:

• Significant reduction in expression of inhibitory receptors such as killer cell immunoglobulin-like receptor 2DL1 (KIR2DL1)

• These changes potentially affect gene expression in several immune cell populations:

  • Macrophages

  • Natural killer (NK) cells

  • Mast cells

Pathways affected by CTNNA2 mutation:

• DNA damage response (DDR) pathway alterations

• Phosphoinositide 3-kinase (PI3K) pathway changes

How does CTNNA2 function as a tumor suppressor in neuroblastoma and other neural crest-derived tumors?

CTNNA2 exhibits multi-faceted tumor suppressor functions in neuroblastoma through several critical cellular processes:

Cell proliferation inhibition:

• Overexpression of CTNNA2 in neuroblastoma cell lines significantly reduces clonogenic capacity

• In SK-N-AS cells, CTNNA2 overexpression reduced proliferation by 52%

• In BE(2)-C cells, proliferation was reduced by 77%

• These effects are observable both in vitro and in vivo xenograft models

Anchorage-independent growth suppression:

• CTNNA2 significantly inhibits colony formation in soft agar assays

• This suggests its role in preventing survival of detached cells, a hallmark of malignancy

Migration and invasion reduction:

• Forced expression of CTNNA2 decreases cell migration and invasion capabilities

• This effect is particularly significant in preventing metastatic spread

Angiogenesis inhibition:

• In vivo studies with xenograft models demonstrated approximately 33% reduction in CD31-stained vessels in CTNNA2-overexpressing tumors

• This anti-angiogenic effect contributes to reduced tumor growth and progression

Cell cycle regulation:

• CTNNA2 overexpression leads to reduced mitotic activity

• Phospho-Histone H3 (ser10) staining showed 50% fewer mitotic cells in CTNNA2-overexpressing tumors compared to controls

Notably, the tumor suppressive effects are more pronounced in non-MYCN-amplified neuroblastoma models compared to MYCN-amplified ones. This aligns with clinical data showing CTNNA2 expression correlates with relapse-free survival only in non-MYCN-amplified neuroblastoma patients . These findings suggest context-dependent tumor suppressor functions that vary based on the molecular subtype of neuroblastoma.

What is the relationship between CTNNA1/CTNNA2 and the MYCN oncogene in neuroblastoma progression?

The relationship between CTNNA1/CTNNA2 and the MYCN oncogene in neuroblastoma reveals a complex molecular interplay with significant clinical implications:

Mutually exclusive prognostic significance:

Differential therapeutic implications:

Molecular independence:

• Despite their functional relationship, there is no correlative expression between MYCN and CTNNA2 in neuroblastoma cell lines

• This suggests they operate through separate but potentially intersecting pathways

Clinical stratification value:

• Analysis of Seeger's dataset (102 gene expression profiles from patients with metastatic neuroblastoma lacking MYCN-amplification) confirmed lower CTNNA2 expression associates with decreased relapse-free survival

• This effect was more pronounced for CTNNA2 (p<0.01) than for CTNNA1 (p=0.046)

These findings have important implications for patient stratification and therapeutic approaches. The data suggest that targeting CTNNA2 pathways may be more beneficial in non-MYCN-amplified neuroblastoma, while MYCN-amplified tumors might require different strategic approaches. This relationship underscores the importance of molecular subtyping in neuroblastoma for both prognostic assessment and therapeutic decision-making.

What are the optimal conditions for using CTNNA1/CTNNA2 antibodies in different experimental techniques?

Optimizing conditions for CTNNA1/CTNNA2 antibody use requires technique-specific considerations:

Western Blot (WB) Optimization:

• Sample preparation: Complete lysis with RIPA or NP-40 buffers containing protease inhibitors

• Protein loading: 20-50μg total protein per lane is typically sufficient

• Expected molecular weight: 100kDa for CTNNA1; 100-105kD for CTNNA2

• Blocking conditions: 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Primary antibody incubation: Typically 1:1000-1:2000 dilution, overnight at 4°C

• Validation controls: Include positive control samples (e.g., BE(2)-C or SH-SY5Y for CTNNA2)

Immunofluorescence/Immunocytochemistry (IF/ICC):

• Fixation: 4% paraformaldehyde (10-15 minutes) preserves epitope accessibility

• Permeabilization: 0.1-0.3% Triton X-100 (5-10 minutes)

• Blocking: 1-3% BSA with 10% normal serum from secondary antibody species

• Primary antibody dilution: Start with 1:100-1:500, optimize as needed

• Counterstains: DAPI for nuclei; phalloidin for F-actin can provide contextual information

• Controls: Include secondary-only controls to assess background

Immunohistochemistry (IHC):

• Antigen retrieval: Critical for paraffin sections; citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Endogenous peroxidase blocking: 3% H₂O₂ for 10 minutes

• Detection systems: HRP-polymer systems often provide better signal-to-noise ratio than ABC method

• Positive controls: Neural tissues for CTNNA2; epithelial tissues for CTNNA1

• Visualization markers: DAB (brown) or AEC (red) chromogens work well

General Optimization Strategies:

• Perform titration experiments to determine optimal antibody concentration

• Test different blocking reagents to minimize background

• Compare different antigen retrieval methods for IHC

• Validate specificity using knockout/knockdown controls when possible

For methodological reliability, researchers should document all optimization steps and include appropriate controls in publications to facilitate reproducibility across different research groups.

How should I interpret conflicting CTNNA1/CTNNA2 expression data between different detection methods?

When faced with conflicting CTNNA1/CTNNA2 expression data across different detection methods, apply this systematic troubleshooting approach:

Understanding method-specific limitations:

Systematic resolution strategy:

• Epitope accessibility assessment:

  • Different antibodies may recognize distinct epitopes with varying accessibility

  • Confirm epitope location relative to protein domains and potential cleavage sites

  • Consider whether post-translational modifications might mask specific epitopes

• Sample preparation variables:

  • Tissue/cell preparation methods affect protein preservation differently

  • Fixation can mask epitopes in IHC but not affect Western blotting

  • Extraction methods might preferentially recover certain protein pools

• Isoform-specific detection:

  • Verify whether detection methods distinguish between CTNNA1 and CTNNA2

  • Consider potential cross-reactivity with other alpha-catenin family members

  • Check for alternative splice variants that might be detected differently

• Integration approach:

  • Correlate protein with mRNA data where possible

  • Consider subcellular localization (cytoplasmic vs. membrane-bound pools)

  • Use orthogonal validation with additional antibodies or methods

• Biological context interpretation:

  • Cell-type heterogeneity in complex tissues may explain apparent discrepancies

  • Expression may be regulated at translational or post-translational levels

  • Protein stability differences might explain mRNA-protein discordance

When possible, validate key findings using genetic approaches (overexpression, knockdown) to confirm the biological relevance of observed expression patterns, as demonstrated in studies where CTNNA2 expression was confirmed both by immunoblotting in cell lines and immunohistochemistry in xenograft tissues .

What are the best gene modulation approaches for studying CTNNA1/CTNNA2 function in vitro and in vivo?

Selecting the optimal gene modulation approach for CTNNA1/CTNNA2 functional studies depends on your specific research questions and model systems:

Overexpression Systems:

Key methodological notes:

• For neuroblastoma studies, researchers have successfully established stably-overexpressed CTNNA2 cells in multiple cell lines (SK-N-AS, BE(2)-C)

• In xenograft models, CTNNA2 overexpression significantly delayed tumor formation and reduced tumor volume in non-MYCN amplified neuroblastoma

Knockdown/Knockout Approaches:

Functional validation strategies:

• Rescue experiments: Re-introducing wild-type or mutant proteins in knockout backgrounds

• Domain mapping: Using truncation or point mutations to identify functional domains

• Orthogonal validation: Confirming phenotypes with multiple independent constructs/guides

In vivo considerations:

• For xenograft studies, confirm protein expression in tumor tissues using immunohistochemistry

• Include appropriate controls (e.g., NSE as a neuronal marker in neuroblastoma studies)

• Assess multiple functional outcomes (tumor growth, angiogenesis, proliferation)

For studying specific mutations like those observed in lung adenocarcinoma patients, CRISPR-based approaches to introduce the exact mutations found in patients provide the most physiologically relevant models to study their impact on immune microenvironment and patient outcomes .

How can CTNNA2 mutation status be used as a biomarker for immunotherapy response in lung adenocarcinoma?

CTNNA2 mutation status shows significant promise as a biomarker for immunotherapy response in lung adenocarcinoma (LUAD) based on multiple converging lines of evidence:

Predictive biomarker rationale:

• Association with immunotherapy response predictors:

  • CTNNA2-mutant LUAD patients exhibit significantly higher tumor mutation burden (TMB)

  • TMB is an established biomarker for immunotherapy efficacy in multiple cancers

  • CTNNA2-mutant patients also show increased tumor neoantigens, which enhance tumor immunogenicity

• Favorable immune microenvironment characteristics:

  • Enhanced expression of chemokine CXCL9, which recruits cytotoxic T cells to tumors

  • Elevated levels of granzyme B (GZMB), indicating active cytolytic immune activity

  • Reduced expression of inhibitory receptor KIR2DL1, potentially relieving immune suppression

• Pathway alterations supporting immunotherapy response:

  • CTNNA2 mutations correlate with increased mutations in DNA damage response (DDR) genes

  • Alterations in PI3K pathway signaling, which can modulate immune cell function and recruitment

Clinical implementation considerations:

• Testing methodology:

  • Whole-exome sequencing (WES) or targeted next-generation sequencing (NGS) panels

  • Consider panel design that includes CTNNA2 and other immune-related genes

• Integration with other biomarkers:

  • Combine with PD-L1 expression status

  • Consider TMB as complementary marker

  • Integrate with gene expression signatures of immune activation

• Patient stratification approach:

  • Primary stratification: CTNNA2 mutant vs. wild-type

  • Secondary considerations: co-mutations in DDR pathways

  • Tumor immunophenotyping to confirm predicted immune alterations

What is the prognostic value of CTNNA1/CTNNA2 expression in different cancer types, and how can this inform clinical decision-making?

The prognostic significance of CTNNA1/CTNNA2 varies across cancer types and molecular contexts, offering valuable insights for clinical stratification:

Neuroblastoma:

• Lower expressions of both CTNNA1 and CTNNA2 correlate with decreased probability of relapse-free survival

• This prognostic value is specifically significant in non-MYCN-amplified neuroblastoma

• CTNNA2 shows stronger prognostic value (p<0.01) than CTNNA1 (p=0.046) in metastatic non-MYCN-amplified disease

• Expression is significantly decreased in stage 4 neuroblastoma compared to other stages

Lung Adenocarcinoma (LUAD):

Clinical implementation framework:

• Cancer-specific assessment approach:

  • Neuroblastoma: Expression level measurement (particularly CTNNA2)

  • LUAD: Mutation status determination through NGS

  • Other cancers: Context-dependent based on tissue origin

• Integration with established prognostic factors:

  • Neuroblastoma: Combine with MYCN status, age, stage

  • LUAD: Integrate with staging, histological subtype, smoking history

• Therapeutic decision guidance:

  • For neuroblastoma: Non-MYCN-amplified patients with low CTNNA2 may require more aggressive therapy

  • For LUAD: CTNNA2-mutant patients might benefit from immunotherapy approaches

  • Treatment stratification should consider molecular context of CTNNA1/CTNNA2 alterations

• Follow-up recommendations:

  • More intensive surveillance for high-risk groups (low CTNNA2 expression in neuroblastoma)

  • Consideration of adjuvant therapy in otherwise intermediate-risk patients

This nuanced understanding of CTNNA1/CTNNA2 prognostic significance can enhance precision medicine approaches in oncology. For example, a neuroblastoma patient with non-MYCN-amplified disease but low CTNNA2 expression might be considered for more intensive therapy despite lacking the MYCN amplification that typically defines high-risk disease .

How might therapeutic approaches targeting CTNNA1/CTNNA2 pathways be developed for cancer treatment?

Developing therapeutic strategies targeting CTNNA1/CTNNA2 pathways represents a promising frontier in cancer therapeutics with multiple potential approaches:

Restoration of CTNNA1/CTNNA2 function:

• Gene therapy approaches:

  • Viral vector-mediated delivery of wild-type CTNNA1/CTNNA2

  • CRISPR-based epigenetic activation of endogenous genes

  • Targeted delivery systems for tumor-specific expression

• Small molecule modulators:

  • Compounds that stabilize existing CTNNA1/CTNNA2 protein

  • Molecules that enhance CTNNA1/CTNNA2 binding to partner proteins

  • Agents that prevent degradation of CTNNA1/CTNNA2

Targeting downstream pathways:

• PI3K pathway inhibition:

  • CTNNA2 mutations alter PI3K pathway signaling

  • Combining PI3K inhibitors with immunotherapy in CTNNA2-mutant tumors

  • Stratification of patients for PI3K inhibitor trials based on CTNNA2 status

• DNA damage response modulation:

  • CTNNA2 mutations associate with increased DDR gene mutations

  • PARP inhibitors or other DDR-targeting agents may show synergy

  • Potential for synthetic lethality approaches

Context-specific therapeutic strategies:

• Neuroblastoma-specific approaches:

  • Restoration of CTNNA2 expression showed significant tumor suppression in non-MYCN-amplified models

  • Combination with conventional chemotherapy for synergistic effects

  • Different strategies required for MYCN-amplified vs. non-amplified disease

• Lung adenocarcinoma approaches:

  • Immunotherapeutic strategies leveraging the altered immune microenvironment in CTNNA2-mutant tumors

  • Combination therapy with immune checkpoint inhibitors

  • Patient selection for immunotherapy based on CTNNA2 mutation status

Biomarker-guided clinical development:

• Patient stratification:

  • CTNNA1/CTNNA2 expression levels for some approaches

  • Mutation status for others (particularly immunotherapy)

  • Consideration of molecular context (e.g., MYCN status in neuroblastoma)

• Response monitoring:

  • Development of pharmacodynamic markers for target engagement

  • Immune monitoring for immunotherapy approaches

  • Serial liquid biopsies to track molecular response

Experimental evidence demonstrates that restoration of CTNNA2 expression significantly inhibits tumor growth and angiogenesis in neuroblastoma xenograft models , providing strong preclinical rationale for therapeutic development. For LUAD, the association between CTNNA2 mutations and favorable immune parameters suggests potential for immunotherapy-based approaches .

What are the most promising avenues for future research on CTNNA1/CTNNA2 in cancer biology?

Future research on CTNNA1/CTNNA2 in cancer biology should pursue these high-priority directions:

Mechanistic investigations:

• Differential functions exploration:

  • Detailed comparison of CTNNA1 vs. CTNNA2 tumor suppressor mechanisms

  • Context-dependent functions across neural vs. non-neural tissues

  • Interplay between adhesion-dependent and adhesion-independent functions

• Mutation-specific effects analysis:

  • Functional consequences of specific CTNNA2 mutations found in lung adenocarcinoma

  • Structure-function relationships through domain-specific mutations

  • Impact of mutations on protein-protein interactions and downstream signaling

• Immune regulation mechanisms:

  • Molecular pathways connecting CTNNA2 mutations to enhanced immune recognition

  • Direct vs. indirect effects on tumor microenvironment

  • Mechanisms of CXCL9 upregulation and KIR2DL1 downregulation in CTNNA2-mutant tumors

Translational research priorities:

• Biomarker development:

  • Prospective validation of CTNNA2 mutation as immunotherapy response predictor

  • Multi-cancer type assessment of CTNNA1/CTNNA2 prognostic value

  • Development of clinically applicable testing protocols

• Therapeutic exploration:

  • Drug screens to identify compounds that restore CTNNA1/CTNNA2 function

  • Combination approaches targeting compensatory pathways

  • Development of delivery systems for gene therapy approaches

• Clinical trial design:

  • Basket trials stratifying by CTNNA2 mutation across tumor types

  • Combination immunotherapy approaches for CTNNA2-mutant tumors

  • Adaptive designs with CTNNA1/CTNNA2 biomarker-guided treatment allocation

Technological innovations needed:

• Advanced model systems:

  • Patient-derived organoids maintaining CTNNA1/CTNNA2 expression patterns

  • Genetically engineered mouse models with tissue-specific alterations

  • Humanized immune system models for studying CTNNA2 mutation effects on immunity

• Single-cell analyses:

  • Spatial transcriptomics to map CTNNA1/CTNNA2 in tumor microenvironment

  • Single-cell immune profiling in CTNNA2-mutant vs. wild-type tumors

  • Clonal evolution studies tracking CTNNA2 mutations during treatment

The convergence of these research directions would significantly advance our understanding of CTNNA1/CTNNA2 biology and accelerate clinical applications, particularly in neuroblastoma where CTNNA2's tumor suppressor role shows promise , and in lung adenocarcinoma where CTNNA2 mutations may predict immunotherapy response .

What are the recommended protocols for detecting CTNNA1/CTNNA2 expression in patient samples for clinical research?

Comprehensive Protocol for CTNNA1/CTNNA2 Detection in Clinical Samples

Immunohistochemistry (IHC) Protocol:

• Tissue preparation:

  • Fix tissue in 10% neutral buffered formalin for 24-48 hours

  • Process and embed in paraffin

  • Section at 4-5μm thickness onto positively charged slides

• Deparaffinization and rehydration:

  • Xylene: 3 changes × 5 minutes each

  • 100% ethanol: 2 changes × 3 minutes each

  • 95% ethanol: 1 change × 3 minutes

  • 70% ethanol: 1 change × 3 minutes

  • Distilled water: 2 changes × 2 minutes each

• Antigen retrieval (critical step):

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Pressure cooker method: 125°C for 30-45 seconds, then 90°C for 10 minutes

  • Allow slides to cool in buffer for 20 minutes

• Immunostaining procedure:

  • Block endogenous peroxidase: 3% H₂O₂ for 10 minutes

  • Protein block: 2.5% normal horse serum for 20 minutes

  • Primary antibody: Anti-CTNNA1/CTNNA2 (1:100-1:200 dilution) for 60 minutes at room temperature or overnight at 4°C

  • Detection system: HRP-polymer for 30 minutes

  • Chromogen: DAB for 5-10 minutes (monitor microscopically)

  • Counterstain: Hematoxylin for 30 seconds

  • Mounting: Permanent mounting medium

• Controls and validation:

  • Positive tissue control: Neural tissue for CTNNA2; epithelial tissue for CTNNA1

  • Negative control: Omission of primary antibody

  • Internal control: Non-neoplastic cells within specimen

RNA-based Expression Analysis:

• RNA extraction from FFPE tissue:

  • Use specialized kits designed for FFPE samples

  • Deparaffinize sections thoroughly

  • Extended proteinase K digestion (3 hours minimum)

  • DNase treatment to remove genomic DNA

  • Quality assessment using Bioanalyzer (accept RIN >2.0 for FFPE)

• RT-qPCR protocol:

  • cDNA synthesis: Use random hexamers and oligo-dT mix

  • Design short amplicons (<100bp) for FFPE-derived templates

  • Primer sequences (suggested):

    • CTNNA1-Forward: 5'-CGCTCTCAACAACTTTGATGCT-3'

    • CTNNA1-Reverse: 5'-CCATTTCATTTGGCAGTCACA-3'

    • CTNNA2-Forward: 5'-GCCATGTGGGAAGTCCTGAT-3'

    • CTNNA2-Reverse: 5'-TGGCAGCAATCCCTTGAAA-3'

  • Reference genes: Use multiple (GAPDH, B2M, ACTB)

  • Perform all reactions in triplicate

• Data analysis:

  • Use 2^-ΔΔCt method for relative quantification

  • Normalize to geometric mean of reference genes

  • Compare to appropriate control samples

Next-Generation Sequencing Approach:

• For CTNNA2 mutation detection:

  • Use targeted panel including full CTNNA2 coding regions

  • Minimum read depth: 500x for reliable variant detection

  • Include common hotspot regions in analysis pipeline

  • Variant calling parameters: VAF threshold ≥5%

• For expression analysis:

  • RNA-Seq with rRNA depletion (preferred over poly-A selection for FFPE)

  • Minimum 20 million paired-end reads per sample

  • Normalize using TPM or FPKM methods

  • Compare to established reference cohorts

These protocols have been successfully implemented in research settings examining CTNNA1/CTNNA2 in neuroblastoma and lung adenocarcinoma samples , providing reliable data for both prognostic assessment and mechanistic studies.

How can I quantify changes in cell adhesion and migration when studying CTNNA1/CTNNA2 function?

Comprehensive Protocols for Quantifying Adhesion and Migration in CTNNA1/CTNNA2 Studies

Cell-Cell Adhesion Assays:

• Hanging drop aggregation assay:

  • Prepare single-cell suspension (2×10⁵ cells/ml)

  • Place 20μl drops on culture dish lid

  • Invert lid over PBS-filled bottom chamber

  • Incubate at 37°C for 24-72 hours

  • Image aggregates and quantify using particle analysis software

  • Metrics: aggregate size, number of single cells, compaction index

• Calcium-switch adhesion assay:

  • Grow cells to confluence in normal calcium medium

  • Switch to low calcium medium (EGTA) to disrupt adhesions

  • Restore normal calcium and monitor junction reformation

  • Fix cells at various timepoints (0, 30, 60, 120, 240 minutes)

  • Immunostain for junctional markers alongside CTNNA1/CTNNA2

  • Quantify: Rate of junction reformation, co-localization coefficients

Cell Migration Assays:

• Wound healing (scratch) assay:

  • Grow cells to 90-100% confluence in 6-well plates

  • Create wound using 200μl pipette tip

  • Wash to remove debris and add serum-reduced medium

  • Image at 0 hour and subsequent timepoints (6, 12, 24 hours)

  • Analysis: Measure wound area/width at each timepoint

  • Calculate percent wound closure and migration rate

• Transwell migration assay:

  • Seed 5×10⁴ cells in serum-free medium in upper chamber

  • Add complete medium to lower chamber as chemoattractant

  • Incubate for 16-24 hours

  • Fix and stain migrated cells with crystal violet

  • Count cells in multiple fields (minimum 5 per well)

  • Normalization: Express as percent of control condition

• Time-lapse microscopy for single cell tracking:

  • Plate cells sparsely on appropriate matrix

  • Acquire images every 10 minutes for 12-24 hours

  • Track individual cells using software (e.g., ImageJ with MTrackJ)

  • Metrics: velocity, directionality, persistence, track length

Invasion Assays:

• Matrigel-coated transwell invasion assay:

  • Coat transwell inserts with growth factor-reduced Matrigel (300μg/ml)

  • Proceed as with migration assay but extend incubation to 24-48 hours

  • Calculate invasion index: (# invading cells/# migrating cells)×100

• 3D spheroid invasion assay:

  • Generate spheroids using hanging drop or ultra-low attachment plates

  • Embed spheroids in collagen I matrix

  • Image every 24 hours for 3-7 days

  • Measure invasion distance and area

  • Quantify: invasion distance, number of invading cells, invasion index

Quantification and Analysis:

• Image acquisition standardization:

  • Use consistent magnification, exposure, and gain settings

  • Acquire z-stacks when necessary for 3D analysis

  • Include scale bars for accurate distance measurements

• Advanced analytical approaches:

  • Automated cell tracking software for unbiased analysis

  • Quantify morphological parameters (aspect ratio, roundness)

  • Measure protrusion dynamics in time-lapse sequences

• Statistical considerations:

  • Perform experiments in triplicate (minimum)

  • Analyze at least 50 cells per condition for single-cell measurements

  • Use appropriate statistical tests (ANOVA with post-hoc for multiple comparisons)

These methodologies have been successfully applied in functional studies of CTNNA2 in neuroblastoma, where forced expression of CTNNA2 was shown to decrease cell migration and invasion capabilities . The combination of multiple complementary assays provides robust evidence for changes in adhesion and migratory behavior upon CTNNA1/CTNNA2 modulation.